# US 2018/0021357 A1 · Methods for treating bacterial infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021357 A1
- Document ID: US20180021357A1
- Status: Published application
- Kind: A1
- Application number: 15/691,977
- Filed: 2017-08-31
- Published: 2018-01-25
- Earliest claimed: 2012-02-22
- Assignees: Ball State Innovation Corporation; Stc.Unm
- Applicants: Ball State Innovation Corporation; Stc.Unm
- Inventors: Susan A. McDowell; Robert E. Sammelson; Larry A. Sklar; Mark K. Haynes
- Web page: https://patentgrep.com/patent/US20180021357A1

## CPC

- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/63: Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to molecules that function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as Staphylococcus aureus and Streptococcus pyogenes.

## Claims

### Claim 1

A method of suppressing bacterial infection comprising:
administering ML 141 or its analogs to cells infected by Staphylococcus,
where the analogs are defined by the following structures:
where
Ar is phenyl, acetamidophenyl (-Ph-NH—CO-Me), or propanamidophenyl (Ph-NH—CO-Et), R is hydrogen, R′ is hydrogen, and Ar′ is methoxyphenyl (-Ph-O-Me), acetamidophenyl (-Ph-NH—CO-Me), or dimethylaminophenyl (Ph-N-Me2); and
where Ar is phenyl and Ar′ is methoxyphenyl (-Ph-O-Me).

### Claim 2 (depends on 1)

The method of claim 1 wherein said bacterial infection is from Staphylococcus aureus.

### Claim 3 (depends on 1)

The method of claim 1 wherein administering includes providing ML 141 or its analogs adjacent to the cells.

### Claim 4 (depends on 1)

The method of claim 1 wherein administering includes testing ML 141 on the cells.

### Claim 5 (depends on 1)

The method of claim 1 wherein administering includes testing at least one analog on the cells.

### Claim 6 (depends on 1)

The method of claim 1 wherein suppressing bacterial infection includes suppressing initial bacterial infection.

### Claim 7 (depends on 1)

The method of claim 1 wherein suppressing bacterial infection includes suppressing persistent bacterial infection.

### Claim 8 (depends on 7)

The method of claim 7 wherein administering includes providing approximately 1 μM of ML 141 or its analogs.

### Claim 9 (depends on 7)

The method of claim 7 wherein administering includes providing approximately 10 μM of ML 141 or its analogs.

### Claim 10 (depends on 1)

The method of claim 1 wherein administering occurs subsequent to the onset of bacterial infection.

### Claim 11 (depends on 1)

The method of claim 1 wherein the cells are animal cells.

### Claim 12 (depends on 1)

The method of claim 1 wherein the cells are human cells.

### Claim 13 (depends on 1)

The method of claim 1 wherein the cells express CDC42.

### Claim 14

A method of suppressing bacterial infection, comprising:
providing a chemical defined by the following structures:
where
Ar is phenyl, acetamidophenyl (-Ph-NH—CO-Me), or propanamidophenyl (Ph-NH—CO-Et), R is hydrogen, R′ is hydrogen, and Ar′ is methoxyphenyl (-Ph-O-Me), acetamidophenyl (-Ph-NH—CO-Me), or dimethylaminophenyl (Ph-N-Me2); and
where Ar is phenyl and Ar′ is methoxyphenyl (-Ph-O-Me); and
providing the chemical to cells infected by Staphylococcus.

### Claim 15 (depends on 14)

The method of claim 14 further comprising providing a pharmaceutically accepted solvent or delivery vehicle selected from the group consisting of polyethylene glycol (PEG), dimethyl sulfoxide, ethanol, and combinations thereof.

### Claim 16 (depends on 15)

The method of claim 15 wherein the solvent or delivery vehicle is polyethylene glycol.

### Claim 17

A method of suppressing bacterial infection comprising:
administering ML 141 or its analogs to a patient infected by bacteria of the genus Staphylococcus,
where the analogs are defined by the following structures:
where
Ar is phenyl, acetamidophenyl (-Ph-NH—CO-Me), or propanamidophenyl (Ph-NH—CO-Et), R is hydrogen, R′ is hydrogen, and Ar′ is methoxyphenyl (-Ph-O-Me), acetamidophenyl (-Ph-NH—CO-Me), or dimethylaminophenyl (Ph-N-Me2); and
where Ar is phenyl and Ar′ is methoxyphenyl (-Ph-O-Me).
